135 related articles for article (PubMed ID: 27008812)
1. DEVELOPMENT OF OLANZAPINE LOADED PNA MICROGELS FOR DEPOT DRUG DELIVERY IN TREATMENT OF SCHIZOPHRENIA: IN VITRO AN IN VIVO RELEASE PROFILE.
Pervaiz F; Ahmad M; Hussain T; Idrees A; Yaqoob A; Abbas K
Acta Pol Pharm; 2016; 73(1):175-81. PubMed ID: 27008812
[TBL] [Abstract][Full Text] [Related]
2. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
[TBL] [Abstract][Full Text] [Related]
3. The dual temperature/pH-sensitive multiphase behavior of poly(N-isopropylacrylamide-co-acrylic acid) microgels for potential application in in situ gelling system.
Xiong W; Gao X; Zhao Y; Xu H; Yang X
Colloids Surf B Biointerfaces; 2011 May; 84(1):103-10. PubMed ID: 21227660
[TBL] [Abstract][Full Text] [Related]
4. Development and Characterization of Olanzapine Loaded Poly(lactide-coglycolide) Microspheres for Depot Injection: In vitro and In vivo Release Profiles.
Pervaiz F; Ahmad M; Li L; Murtaza G
Curr Drug Deliv; 2019; 16(4):375-383. PubMed ID: 30588882
[TBL] [Abstract][Full Text] [Related]
5. Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.
Town AR; Giardiello M; Gurjar R; Siccardi M; Briggs ME; Akhtar R; McDonald TO
Nanoscale; 2017 May; 9(19):6302-6314. PubMed ID: 28368063
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
7. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
8. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
Hill AL; Sun B; McDonnell DP
Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.
Seju U; Kumar A; Sawant KK
Acta Biomater; 2011 Dec; 7(12):4169-76. PubMed ID: 21839863
[TBL] [Abstract][Full Text] [Related]
10. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release.
Lu Y; Yu Y; Tang X
J Pharm Sci; 2007 Dec; 96(12):3252-62. PubMed ID: 17721936
[TBL] [Abstract][Full Text] [Related]
11. Drug safety evaluation of olanzapine pamoate.
Schöttle D; Kuhnigk O; Naber D
Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627
[TBL] [Abstract][Full Text] [Related]
12. Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation.
Wang D; Zhao J; Liu X; Sun F; Zhou Y; Teng L; Li Y
Eur J Pharm Sci; 2014 Aug; 60():40-8. PubMed ID: 24815944
[TBL] [Abstract][Full Text] [Related]
13. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
[TBL] [Abstract][Full Text] [Related]
15. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
[TBL] [Abstract][Full Text] [Related]
17. DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model.
Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
Int J Pharm; 2018 Apr; 541(1-2):198-205. PubMed ID: 29474898
[TBL] [Abstract][Full Text] [Related]
18. Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate.
Alakhov V; Pietrzynski G; Patel K; Kabanov A; Bromberg L; Hatton TA
J Pharm Pharmacol; 2004 Oct; 56(10):1233-41. PubMed ID: 15482637
[TBL] [Abstract][Full Text] [Related]
19. In vitro transdermal and biological evaluation of ALA-loaded poly(N-isopropylacrylamide) and poly(N-isopropylacrylamide-co-acrylic acid) microgels for photodynamic therapy.
Gómez C; Benito M; Katime I; Teijón JM; Blanco MD
J Microencapsul; 2012; 29(7):626-35. PubMed ID: 22494064
[TBL] [Abstract][Full Text] [Related]
20. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
